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Tachykinins of different classes (NKl, NK2, NK3) caused the concentration-dependent sy thesis of IP, in rat submandi- 
bular acinar cells with the potency rank order of NKI z NK2 > NK3. Enhancement of IP, was not affected by pertussis 
toxin treatment. The reverse rank order was found in the tachykinin inhibition of isoproterenol-induced CAMP synthesis 
and this inhibition was abolished by pertussis toxin, an inactivator of the adenylate cyclase Gi regulatory protein. It is 
suggested that different tachykinin receptor subtypes are preferentially coupled to phospholipase C or adenylate cyclase 
by separate G regulatory proteins in rat submandibular acinar cells. 
Substance P; Tachykinin receptor; Phospholipase C; Adenylate cyclase; G protein; Pertussis toxin 
1. INTRODUCTION 
In an earlier study, we reported that two cal- 
cium-mobilizing agonists of different classes, SP 
and carbachol, stimulated the secretion of acinar 
cell mucin by rat submandibular gland [I]. These 
agonists also caused the hydrolysis of membrane 
PIP2 resulting in increased cellular levels of IP3 
[ 1,2]. In many cell types, Ca2+-mobilizing agonists 
exert their physiological effect through receptor- 
linked activation of PLC, leading to the hydrolysis 
of membrane PIP2. Both IPs and DC breakdown 
products then act as second messengers in stim- 
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ulus-response coupling [3,4]. There is strong 
evidence that a guanine nucleotide-binding, G 
regulatory protein couples stimulated receptors to 
PLC activation [5]. In addition to their effects on 
mucin release and PIP2 hydrolysis, SP and car- 
bachol reduced the mucosecretory response voked 
by the ,&adrenergic agonist, IPR [l]. 
Recent studies in our laboratory showed that 
carbachol antagonizes the submandibular muco- 
secretory response to IPR by its inhibition of IPR- 
induced CAMP synthesis. It was further demon- 
strated that this muscarinic effect was mediated by 
the Gi regulatory protein of the adenylate cyclase 
complex which could be inactivated by treatment 
with pertussis toxin. Carbachol stimulation of 
PLC was, in contrast, mediated by a different Gp 
protein which was PT-insensitive (Fleming et al., 
submitted). It was therefore proposed that mus- 
carinic receptors are coupled to two signal trans- 
duction pathways by discrete G-proteins that may 
be differentiated by their response to PT. 
The tachykinin agonist, SP, has many effects in 
common with carbachol in the submandibular 
model, including the inhibition of ,&adrenergic- 
induced secretion and the stimulation of PIP2 
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hydrolysis [l]. The present investigation was 
therefore undertaken to examine whether SP ac- 
tions are also mediated in the phosphoinositide 
and CAMP pathways by different regulatory G- 
proteins. Moreover, since the existence of multiple 
tachykinin receptors - NKl, NK2 and NK3 - has 
been established [6], we sought to determine 
whether specific receptor subtypes may be pre- 
ferentially linked to each signal transduction 
pathway. 
variance and Duncan’s multiple range test. Values of p < 0.05 
were considered significant. 
3. RESULTS 
3.1. IP3 studies 
2. MATERIALS AND METHODS 
2.1. Materials 
Substance P, physalaemin, eledoisin, kassinin, NKA, NKB 
and SP-ME were obtained from Peninsula Laboratories, Bel- 
mont, CA. Purified collagenase, CLSPA grade, was obtained 
from Worthington, Freehold, NJ. myo-[2-3H]Inositol was a 
product of Amersham, Oakville, Ontario, Canada. Purified 
pertussis toxin was supplied by List Biological Laboratories, 
Campbell, CA. New England Nuclear, Montreal, Quebec, 
Canada provided ‘251-~AMP radioimmunoassay kits. Hank’s 
balanced salt solution was obtained from Gibco, Burlington, 
Ontario, Canada. All other reagents were from Sigma, St. 
Louis, MO. 
In the absence of added tachykinins, basal 3H- 
IP3 accumulation over 10 min was 321 + 21 
dpm/mg protein. Incubation of cells with the 
tachykinins produced concentration-dependent in- 
creases in IP3 levels (fig.1). Although all the 
agonists produced a similar maximal stimulation 
of IP3 to around three times control level, there 
were obvious variations in their potencies (table 1). 
Calculated pD2 values fell into three groups that 
were statistically different (table 1). Thus, SP, 
physalaemin and SP-ME were more potent in 
enhancing IP3 levels than were kassinin, eledoisin 
and NKA; and the latter three tachykinins were 
more potent than NKB. 
Preincubation of cells with PT had no effect on 
basal or SP-induced IP3 production (not shown). 
3.2. CAMP studies 
2.2. Methods 
Collagenase-dispersed rat submandibular gland acinar cells 
were prepared as previously described [l]. Dispersed cells were 
incubated for 60 min in supplemented Hank’s balanced salt 
solution (HBSS) containing 35 pCi myo-[2-‘Hlinositol (12.3 
Ci/mmol). The cells were washed once in medium containing 
5 mM unlabelled inositol and resuspended in 1 ml aliquots of 
inositol-free medium. Test preparations were challenged with a 
range of concentrations of several tachykinin agonists: SP, 
physalaemin, eledoisin, kassinin, NKA, NKB or SP-ME for 
10 min. The reaction was stopped by addition of 1 ml ice-cold 
TCA (6% final concentration). Inositol phosphates were ex- 
tracted from the soluble fraction by anion-exchange 
chromatography on Bio-Rad AG 1 x 8 formate resin as de- 
scribed previously [l] and quantitated by scintillation counting. 
In some experiments, cells were exposed to pertussis toxin 
(200 ng/ml, 1 h) before agonist treatment. 
Substance P, NKA and NKB were chosen as 
representative agonists of tachykinin classes for 
CAMP studies. These agonists alone, in concentra- 
tions up to lo-’ M, did not affect CAMP levels in 
mucus acinar cells. IPR (10e5 M) caused an eight- 
fold increase in CAMP level from 17.5 + 
400 
For CAMP studies, collagenase-dispersed submandibular 
cells were exposed to various concentrations of NKA, NKB or 
SP for 2 min followed by IPR (10-s M) for 10 min. Additional 
experimental groups received either IPR alone (10 min), 
tachykinins alone (12 min) or were left untreated as controls. 
The cells were precipitated with 6% TCA and centrifuged at 
2500 X g for 15 min. The supernatant fluid was extracted with 
water-saturated ether and assayed for CAMP by radioim- 
munoassay as described previously [7]. In some experiments, 
cells were preincubated with pertussis toxin (200 ng/ml, 1 h) 
before agonists were added. 
-lo!2 [Ml 
Protein content of the acinar cells was determined by the 
method of Lowry et al. [S]. 
Fig. 1. Concentration-response curves for three representative 
tachykinins in the stimulation of IP3 levels in rat submandibular 
acinar cells after 10 min treatment. IP3 was assayed as 
described in section 2. Values are means + SE, n = 4. (0) 
Results were examined statistically by two-way analysis of Neurokinin A; (0) neurokinin B; (A) substance P. 
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Table 1 
pDz values for tachykinin agonists in the stimulation of IPs in 
dispersed cells of rat submandibular gland 
Tachykinin PDZ 
Substance P 8.63 * 0.06 
Physalaemin 8.86 * 0.13 
SP methyl ester 8.10 k 0.12 
Kassinin 7.84 k 0.02a 
Eledoisin 7.51 & 0.03= 
Neurokinin A 7.66 k 0.19= 
Neurokinin B 7.07 + O.llb 
a Significantly different from SP, physalaemin or SP methyl 
ester, p < 0.05 
b Significantly different from all other tachykinin agonists, p < 
0.05 
Dispersed acinar cells were exposed to various agonists for 
10 min and IP3 measured as described in section 2. pDz( - log 
E&J) was calculated from four separate concentration response 
curves for each agonist. Values are means * SE, n = 4 
2.9 pm/mg protein in controls to 137 f 22 pg/mg 
protein in stimulated cells. Pretreatment of cells 
with varying concentrations of NKA (10-10-10-7 
M), NKB (10-13-10-9 M) or SP (10-9-10-6 M) 
elicited a concentration-dependent reduction of the 
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-log [Ml 
Fig.2. Concentration-response curves for tachykinin inhibition 
of CAMP levels induced by lo-’ M isoproterenol in rat 
submandibular acinar cells. Cells were incubated with the 
tachykinins for 2 min, followed by IPR for 10 min. CAMP was 
assayed by RIA. Results are expressed as percent inhibition of 
the CAMP levels stimulated by IPR alone. Values are means f 
SE, n = 6. (0) Neurokinin A; (0) neurokinin B; (A) substance 
P. 
Table 2 
pDz values for tachykinin agonist inhibition of the 
isoproterenol-induced CAMP response in dispersed cells of rat 
submandibular gland; and the maximum inhibition of IPR- 
CAMP response elicited by these agonists 
Tachykinin PDZ %  inhibition of 
IPR-CAMP response 
Neurokinin B 10.90 f 0.30 31.0 + 3.4 
Neurokinin A 9.03 * 0.01 28.3 + 3.1 
Substance P 7.65 f 0.15 32.0 t 4.5 
Effects of preincubation of acinar cells with three tachykinins 
on the IPR-induced CAMP response were assessed by RIA as 
described in section 2. Different optimal concentrations of the 
agonists inhibited the CAMP response to the same extent but 
their pD2 values are significantly different from each other @ < 
0.01). Values are means f SE, n = 6 
shows the pD2 values of the tachykinins for the 
CAMP-inhibition response. NKB was significantly 
more potent than both NKA and SP @ < 0.01). At 
optimally effective concentrations (NKB, 10e9 M; 
NKA, lo-* M; and SP, 10e7 M), there was no 
significant difference in the degree of inhibition 
elicited by these agonists (table 2). 
Pretreatment of cells with PT alone (200 ng/ml) 
or in combination with SP (lop7 M) did not affect 
basal concentration of CAMP. However, SP- 
induced reduction of the IPR-CAMP response was 
abolished after 1 h preincubation with PT (table 
3). 
Table 3 
Effect of pertussis toxin on the SP-induced inhibition of 
elevated CAMP levels elicited by isoproterenol stimulation in rat 
submandibular acinar cells 
Pre- Control SP Isoproterenol SP ( 10m7 M) + 
treatment (1O-7 M) (10-s M) isoproterenol 
(lo-’ M) 
-PT 12.0 * 1.3 14.0 + 2.0 100 60 ZIZ 5.1a 
+PT 14.1 k 1.213.2 ZL 0.9 107 k 2.9 103 * 11.4 
a p < 0.01 vs isoproterenol 
Dispersed acinar cells were preincubated in the presence (+ P’U 
or absence (- PT) of pertussis toxin (200 ng/ml; 1 h) then 
exposed to SP (12 min); IPR (12 min); or SP (2 min) followed 
by IPR (10 min). CAMP was measured by RIA as described in 
section 2. For normalization of the results of several 
experiments, values are expressed as percentage of the 11% 
response. Values are mean + SE, n = 6 
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4. DISCUSSION 
The results of this study extend our earlier obser- 
vations [l] on the effects of SP on stimulus- 
response coupling mechanisms in submandibular 
cells, by confirming that several additional tachy- 
kinin/neurokinin agonists stimulate PIP2 
hydrolysis and also inhibit the &adrenergic-CAMP 
response in the model. 
It has been shown in many studies that Cazf- 
mobilizing receptors, including tachykinin and 
muscarinic, are coupled to PLC by a G regulatory 
protein [3,4]. We have recently established that a 
G-protein (G,) is involved in the phosphoinositide 
effect in submandibular cells and that the protein 
is not inactivated by pertussis toxin (Fleming et al., 
submitted). This PT-resistant property is consis- 
tent with that of the PLC-associated G-protein in 
heart cells [9], pancreas [lo] and liver [ 111. We 
have now shown in the present study that tachyki- 
nin-induced PIP2 hydrolysis is also PT-insensitive. 
In contrast, the tachykinin effect of reducing ,& 
adrenergic-induced CAMP levels is abolished by 
PT, which is known to inactivate the Gr protein of 
the adenylate cyclase complex by ADP-ribosyla- 
tion of the a-subunit. This finding is compatible 
with our earlier observation that SP inhibition of 
the IPR mucosecretory response in the model is 
reversed by PT treatment [2]. Taken together, 
these results suggest hat tachykinin receptors are 
coupled separately to the phosphoinositide and 
CAMP pathways by two different regulatory pro- 
teins in the same way as are muscarinic receptors 
in submandibular cells. 
Based on the rank order of potency, agonist 
selectivity and radioligand binding [6,12], the 
tachykinin receptors have been classified into 3 
subtypes - NKl, on which SP is more active than 
NKA and NKB; NK2, on which NKA > NKB > 
SP; and NK3, where NKB > NKA > SP. The pre- 
sent study suggests that PIP2 hydrolysis is coupled 
to the NKl receptor subtype, since SP, SP-ME and 
physalaemin were approximately equipotent but 
were considerably more potent than NKA and 
NKB. Hanley et al. [13] have shown that phos- 
phoinositide hydrolysis in rat parotid cells is also 
mediated via NKl receptors. However, there is 
evidence that, depending on the tissue, all the 
receptor subtypes are capable of mediating PIP2 
hydrolysis. Thus PIP2 hydrolysis has been ob- 
served in NK2-type tissues such as the rat ileum 
and hamster urinary bladder [14,15]. Substance P 
and related tachykinins also stimulate inositol 
phospholipid hydrolysis in guinea pig ileum longi- 
tudinal muscle-myenteric plexus preparations, an 
example of NK3-type tissue [16]. 
A reverse order of potency was obtained for the 
tachykinin inhibition of the IPR-CAMP response. 
Here the rank order was NKB % NKA > substance 
P, indicating an NK3-mediated response. To the 
best of our knowledge, this is the first classifica- 
tion of the tachykinin receptor modulating the 
adenylate cyclase system in a salivary gland model. 
It is also the first report of an NK3-mediated 
response in rat submandibular gland in vitro. 
The results on PIP2 hydrolysis correlate well 
with radioligand and autoradiographic evidence 
that acinar cells of rat submandibular gland con- 
tain predominantly NKl-binding sites as we11 as a 
smaller number of NK2 or NK3 sites [17]. Our 
observations are also in agreement with the finding 
that NKl agonists, physalaemin and SP stimulate 
mucus and amylase secretion in the gland [ 181. The 
fact that NK3 receptors modulate adenylate 
cyclase activity in this study now suggests a 
physiological function for the small number of this 
receptor subtype found in radioligand-binding 
studies. Thus, as indicated by the work of Buck 
and Burcher [17] and by the present study, the rat 
submandibular gland may not be a pure NKI 
tissue. Murray et al. [19] have recently proposed 
the presence of three tachykinin receptor subtypes 
in rat salivary glands. 
In conclusion, these results suggest hat the ef- 
fects of tachykinins on the phosphoinositide and 
CAMP pathways are preferentially mediated by 
different tachykinin receptor subtypes. Our 
findings further suggest that these receptor sub- 
types are coupled to the two effector systems by 
discrete G regulatory proteins. 
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